EMA recommends pembrolizumab for the adjuvant treatment of RCCEMA| PembrolizumabUrologytimes.com reports that the European Medicines Agency’s Committee for Medicinal Products for Human Use ...
NICE rejects pembro+axitinib therapy for aRCCAxitinib| NICE| PembrolizumabKidney cancer community strongly disagrees with NICE decision not to approve pembrolizumab with axitinib ...
Researchers underscore efficacy of Pembrolizumab+Axitinib in treating advanced RccAxitinib| PembrolizumabASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell ...
Europe Adopts Pembrolizumab + Axitinib as 1st-Line Treatment for Advanced RCCAxitinib| PembrolizumabThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), based in ...